Matters of legal in nature including licensing, intellectual property, and lawsuits.
CHALFONT ST. GILES, UK – 3 January, 2017 – GE Healthcare’s Life Sciences business announced today that it has acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside the USA, Canada and Mexico. GE Healthcare’s strong industry presence and existing customer and... Read more
Agilent fortifies its target-enrichment portfolio through its planned acquisition of Multiplicom N.V. SANTA CLARA, Calif. & NIEL, Belgium–(BUSINESS WIRE)–Dec. 20, 2016– Agilent Technologies Inc. (NYSE:A) and Multiplicom N.V. today announced that they have signed a definitive agreement under which Agilent will acquire Multiplicom, a leading European diagnostics company with state-of-the-art genetic testing technology and products.... Read more
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus Kusatsu/Shiga, Japan — December 15, 2016 — Takara Bio Inc. (Takara) announced today that it has entered into an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for co-development and commercialization in Japan of the oncolytic virus... Read more
November 28th 2016 – GE Healthcare has taken a 20% stake in global venture management company Pilot Lite Ventures (PLV), expanding its consulting business as it seeks to tap into an estimated $28 billion global market in unexploited healthcare and wellness R&D, orphaned IP and early-stage technology. GE Healthcare Partners currently offers analytics-based consulting solutions... Read more
UC San Francisco’s Center for Digital Health Innovation and GE Healthcare today announced a partnership to develop a library of deep learning algorithms – complex problem-solving formulas – that will empower clinicians to make faster and more effective decisions about the diagnosis and management of patients with some of the most common and complex medical... Read more
–Patent No. 1802752 “Parellel Patch Clamp System” Upheld in European Patent Office- Sunnyvale, California – October 7, 2016. Molecular Devices, LLC, a company committed to providing innovative analytical solutions for protein and cell biology, announced today that its European Patent No. 1802752 titled “Parallel Patch Clamp System” was upheld by the European Patent Office in... Read more
CHALFONT ST. GILES, UK – 30 September 2016 –At the International Society for Cellular Therapy’s Regional Meeting in Memphis, TN, GE Healthcare’s recently acquired Biosafe Group introduces Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing and final formulation during cell processing. Combined with GE... Read more
Evry, France, and Bergisch Gladbach, Germany, September 28th, 2016 – Genethon, a leader in the field of gene therapy treatments for rare diseases, and Miltenyi Biotec, a global front-runner in cell processing and related technologies in cell therapy, have announced the execution of an exclusive license to the patents and trademarks for the development and commercialization... Read more
Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Neurons iCell Astrocytes iCell DopaNeurons iCell GlutaNeurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts iCell Endothelial Cells... Read more
Chalfont St Giles, UK – 23 August 2016 – In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of... Read more